

bortezomib-VELCADE® MedicationPresertification Request **Precertification Request**

Page 1 of 2

Aetna Precertification Notification Phone: 1-866-752-7021

FAX: 1-888-267-3277

For Medicare Advantage Part B:

Places indicate: □ S	•		mpleted and legible for p	orecertification rev	iew.)	Please Use Me	dicare Request Form
Please indicate: ☐ S			last treatment/	1			
□ ○ Precertification Reque			· · · · · · · · · · · · · · · · · · ·	Phone:		Fax:	
A. PATIENT INFORMA	<u> </u>						
First Name:	HON.		Last Name:			DOB:	
Address:			·	City:		State:	ZIP:
Home Phone:		Work Phone:		Cell Phone:		Email:	
	lhe er				Alleraine	Liliali.	
Patient Current Weight: _		kgs Palleni	i Height:inches	orcris	Allergies:		
B. INSURANCE INFOR			Doos nationt have ath	or onverge?	□ Voc. □ No.		
Aetna Member ID #: Group #:			Does patient have other coverage? Yes No If yes, provide ID#: Carrier Name:				
Insured:			Insured:				
Medicare: ☐ Yes ☐ N	o If ves. provid	le ID #:	Me	dicaid: ☐ Yes	☐ No If yes, prov	ide ID #:	
C. PRESCRIBER INFO							
First Name:			Last Name:		(Check One	e):	D.O.
Address:				City:	(State:	ZIP:
Phone:	Fax:		St Lic #:	NPI#:	DEA #:	1010101	UPIN:
Provider Email:	ı ax.			ΙΝΙ Ι π.	DLA #.	Phone:	Of IIV.
			Office Contact Name:			Prione:	
Specialty (Check one):		·					
D. DISPENSING PROV		TRATION INFOR	RMATION				
Place of Administration					Provider/Pharmac		
Self-administered	=	ian's Office				☐ Retail Pharr	nacy
Outpatient Infusion C		one:			,	Other	
Center Name: _ Home Infusion Cente		one.		Name:			
				Address:			
Agency Name: Administration code(s) (CPT):			Dhamai			Fax:	
Address:				TIN:		PIN:	
E. PRODUCT INFORMA	ATION						
Request is for: D borte		CADE Dose:		Fregu	ency:		
F. DIAGNOSIS INFORM					-		
Primary ICD Code:			Secondary ICD Cod			CD Code:	
G. CLINICAL INFORMA			=				
For ALL Requests (clinic							
Please indicate the patien			m²				
☐ Yes ☐ No Will the	e patient's dose e	xceed 1.6 mg/m ² ?	?				
☐ Yes ☐ No Does to							
For Initiation Requests (ntation required	for all requests):				
Acute lymphoblastic		ich the requested	medication will be used:	□ Palancad d	lisease 🔲 Refracto	n essesib v	Other
Adult T-cell leukemia	· ·	cii iile requesieu	medication will be used.	☐ IXelapsed d	ilisease 🔲 Nellacio	y disease	Ottlei
☐ Yes ☐ No Will the	, .	cation be used as	a single agent?				
Please indicate the place in therapy in which the requested			d medication will be use	d:	erapy 🔲 Subsequ	ent therapy	
☐ Antibody mediated re	-	organ					
Classic Hodgkin Lym		ich the requested	modication will be used:	□ Polancod d	lisaasa 🗆 Pofrasta	av dispaso	Other
Please indicate the clinical setting in which the requested medication will be Follicular lymphoma			medication will be used.	☐ Relapsed d	lisease Refracto	y disease 🔲	Other
Please indicate the clinical setting in which the requested medi			medication will be used:	☐ Relapsed d	lisease 🔲 Refracto	y disease 🔲	Other
☐ Kaposi sarcoma				. =			
Please indicate the place in therapy in which the requeste			d medication will be use	d:	erapy 🗌 Subsequ	ent therapy	
☐ Mantle cell lymphoma☐ Multicentric Castlema							
_		hich the requeste	d medication will be use	d: First-line th	erapy 🔲 Subsequ	ent therapy	
☐ Multiple myeloma	. •	·				.,	



bortezomib-VELCADE Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification

Phone: 1-866-752-7021 FAX: 1-888-267-3277

For Medicare Advantage Part B:

0	u.ou.	0 / ta ra.	ugo .	u – .
Please	Use I	Medicare	Reque	st Forn

Patient First Name	Patient Last Name	Patient Phone	Patient DOB					
G. CLINICAL INFORMATION (continue	ed) – Required clinical information	must be completed in its entirety for	all precertification requests.					
☐ POEMS (polyneuropathy, organomeg	jaly, endocrinopathy, monoclonal	protein, skin changes) Syndrome						
☐ Yes ☐ No Will the requested medi	cation be used in combination with o	lexamethasone?						
☐ Systemic light chain amyloidosis								
☐ Waldenstrom macroglobulinemia/lym	☐ Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma							
For Continuation Requests (clinical docu	mentation required for all reques	its):						
☐ Yes ☐ No Has the patient experienced unacceptable toxicity or disease progression while on the current regimen?								
H. ACKNOWLEDGEMENT								
Request Completed By (Signature Re	quired):		Date: //	-				
Any person who knowingly files a reque any insurance company by providing ma insurance act, which is a crime and subje	aterially false information or conce	eals material information for the purp						

The plan may request additional information or clarification, if needed, to evaluate requests.